Compare Sana Biotechnology Inc (SANA) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs TeraWulf Inc — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $873.84M), while TeraWulf Inc trades at $20.01 (market cap $9.35B). The key difference: TeraWulf Inc is far larger — about 10.7× Sana Biotechnology Inc's market cap, and TeraWulf Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | WULF | |
|---|---|---|
Market Cap | $873.84M | $9.35B |
Sector | Health | Technology |
52-Week High | $5.92 | $28.98 |
52-Week Low | $2.68 | $4.76 |
Enterprise Value | $848.03M | $12.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.14, down 0.32% with bearish technical indicators despite strong analyst support. The company shows significant financial challenges with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn improved from -$55M to -$12M in 2026. Recent positive developments include a Zacks upgrade to Buy and groundbreaking clinical data published in NEJM.
Investment outlook remains speculative with high execution risk given substantial losses, but strong analyst consensus (82% Buy ratings) reflects optimism about SANA's innovative cell therapy pipeline. Key risks include continued cash burn and clinical trial outcomes, while potential catalysts include successful product development in diabetes and CAR-T therapies.
WULF trades at $18.86, up 3.85% today, but remains in a bearish technical trend. The company reported a net loss of -$661.42M in 2025 with a -611.46% net margin, though it secured a significant 20-year, $19B AI infrastructure deal with Anthropic. Analyst consensus is unanimously bullish with a $37.22 price target, citing long-term AI data center growth potential despite near-term profitability challenges.
The outlook hinges on successful execution of the Anthropic partnership to drive future revenue, but high valuation multiples and persistent losses pose substantial risks. Investors face volatility from operational cash burn and sector sentiment swings, requiring careful risk assessment against transformative AI infrastructure opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
